Drug Profile


Alternative Names: CP-533,536

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Pyridines; Small molecules
  • Mechanism of Action Osteogenesis stimulants; Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Fracture

Most Recent Events

  • 27 Sep 2010 Discontinued - Phase-II for Fracture in Australia (SC)
  • 27 Sep 2010 Discontinued - Phase-II for Fracture in Bosnia-Herzegovina (SC)
  • 27 Sep 2010 Discontinued - Phase-II for Fracture in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top